Effects of informant replacement in Alzheimer's disease clinical trials.

Introduction: Alzheimer's disease (AD) trials require enrollment with an informant.

Methods: We assessed relationships between informant replacement and Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scores across four AD trials. Using generalized estimating equations, we examined associations between replacement and change in ADCS-ADL between successive visits.